No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction

Michelle Maugham; I Seim; P B Thomas; G J Crisp; E T Shah; A C Herington; K A Brown; L S Gregory; C C Nelson; P L Jeffery; L K Chopin

doi:10.1371/journal.pone.0198495

Back

No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction

Journal article

Open access

Peer reviewed

No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction

Michelle Maugham, I Seim, P B Thomas, G J Crisp, E T Shah, A C Herington, K A Brown, L S Gregory, C C Nelson, P L Jeffery, …

PLoS One, Vol.13(11), e0198495

2018

DOI: https://doi.org/10.1371/journal.pone.0198495

Files and links (2)

pdf

PDF - Published Version (Open Access)826.31 kBDownload View

Published VersionPDF - Published Version (Open Access)CC BY V4.0, Open Access

url

https://doi.org/10.1371/journal.pone.0198495View

Published Version

Abstract

Ghrelin is a peptide hormone which, when acylated, regulates appetite, energy balance and a range of other biological processes. Ghrelin predominately circulates in its unacylated form (unacylated ghrelin; UAG). UAG has a number of functions independent of acylated ghrelin, including modulation of metabolic parameters and cancer progression. UAG has also been postulated to antagonise some of the metabolic effects of acyl-ghrelin, including its effects on glucose and insulin regulation. In this study, Rag1-/- mice with high-fat diet-induced obesity and hyperinsulinaemia were subcutaneously implanted with PC3 prostate cancer xenografts to investigate the effect of UAG treatment on metabolic parameters and xenograft growth. Daily intraperitoneal injection of 100 μg/kg UAG had no effect on xenograft tumour growth in mice fed normal rodent chow or 23% high-fat diet. UAG significantly improved glucose tolerance in host Rag1-/- mice on a high-fat diet, but did not significantly improve other metabolic parameters. We propose that UAG is not likely to be an effective treatment for prostate cancer, with or without associated metabolic syndrome.

Details

Title: No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction
Authors: Michelle Maugham (Author) - Queensland University of Technology
I Seim (Author)
P B Thomas (Author)
G J Crisp (Author)
E T Shah (Author)
A C Herington (Author)
K A Brown (Author)
L S Gregory (Author)
C C Nelson (Author)
P L Jeffery (Author)
L K Chopin (Author)
Publication details: PLoS One, Vol.13(11), e0198495
Publisher: Public Library of Science
Date published: 2018
DOI: 10.1371/journal.pone.0198495
ISSN: 1932-6203
Copyright note: Copyright © 2018 Maugham et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Organisation Unit: School of Health - Biomedicine; University of the Sunshine Coast, Queensland; School of Health and Sport Sciences - Legacy; School of Health and Behavioural Sciences - Legacy
Language: English
Record Identifier: 99450952502621
Output Type: Journal article

Metrics

10 File views/ downloads

39 Record Views

3 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Web Of Science research areas: Endocrinology & Metabolism

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites